← Viking Therapeutics overview

Viking Therapeutics vs AbbVie: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Viking Therapeutics Inc (VKTX)

Q3 2026
▲2▼1

Viking's VK2735 shines, but cash burn and dilution weigh

  • VK2735 efficacy and dosing VK2735 showed 22% weight loss and up to 97% maintained on less-frequent dosing, strong efficacy plus convenience that positions it against Lilly and Novo.

    This is the key new clinical data that drove optimism in the quarter.

  • Takeover speculation Vertex's $10B Crinetics deal fueled takeover speculation, and an unsettled oral GLP-1 market keeps Viking's pipeline valuable.

    This new external event increased investor interest in Viking as a potential acquisition target.

  • Widening losses and dilution Q2 net loss widened to $128.1M as R&D surged, and an upsized $500M stock and convertible note offering raises dilution concerns.

    These new financial developments create a real counterweight to the positive pipeline news.

  • Long wait and valuation divide Phase 3 data remain years away, and analyst valuations diverge wildly ($92.72 vs. $14.02). Cash burn and funding needs will likely overhang the stock until VK2735 reaches market.

    This highlights the ongoing uncertainty and long timeline that keep the stock volatile.

August 2026
▲2▼1

Viking's VK2735 data wows, but $500M raise dilutes

  • VK2735 maintenance data: 22% weight loss, up to 97% kept on less-frequent dosing Viking reported that its obesity drug VK2735 produced 22% weight loss and patients kept up to 97% of it when switched to every-other-week shots (90% monthly), versus 61% on placebo. This is the big driver: strong efficacy plus a more convenient schedule makes the drug a real contender against Lilly and Novo, lifting hopes for future sales and partnership or buyout interest.

    This is the single biggest new event moving VKTX, directly boosting its competitive position and long-term value.

  • Upsized $500M stock and convertible note offering raises dilution worries Viking priced an upsized raise: 7.85 million shares at $35 plus $225 million of convertible notes, up from $200 million each. The cash funds VK2735 and VK3019 trials, but selling new shares dilutes existing owners and the convertible notes could dilute later. This is the main counterweight to the good data.

    It is the key new financing event that pressures the stock by diluting current shareholders.

  • Big pharma GLP-1 race leaves room for Viking Lilly's Mounjaro and Zepbound sales surged while Novo's Ozempic and Wegovy stalled, and Lilly's oral pill Foundayo is just starting. Viking's oral VK2735 phase 3 is planned for late 2026. A fast-growing market with an unsettled oral segment keeps Viking's pipeline valuable, supporting the stock.

    It shows the competitive landscape that makes Viking's oral and injectable programs strategically valuable.

  • Cash burn and capital needs remain the overhang Viking used about $96 million last quarter and cash fell to $502 million from $706 million. Management says cash lasts into 2028, but the new raise confirms trials are expensive. Until VK2735 reaches market, funding needs and dilution risk will keep weighing on the stock even as data improves.

    It explains the persistent financial pressure that offsets clinical optimism for VKTX.

Latest
▲2▼1

Viking's VK2735 data wows, but $500M raise dilutes

  • VK2735 maintenance data: 22% weight loss, up to 97% kept on less-frequent dosing Viking reported that its obesity drug VK2735 produced 22% weight loss and patients kept up to 97% of it when switched to every-other-week shots (90% monthly), versus 61% on placebo. This is the big driver: strong efficacy plus a more convenient schedule makes the drug a real contender against Lilly and Novo, lifting hopes for future sales and partnership or buyout interest.

    This is the single biggest new event moving VKTX, directly boosting its competitive position and long-term value.

  • Upsized $500M stock and convertible note offering raises dilution worries Viking priced an upsized raise: 7.85 million shares at $35 plus $225 million of convertible notes, up from $200 million each. The cash funds VK2735 and VK3019 trials, but selling new shares dilutes existing owners and the convertible notes could dilute later. This is the main counterweight to the good data.

    It is the key new financing event that pressures the stock by diluting current shareholders.

  • Big pharma GLP-1 race leaves room for Viking Lilly's Mounjaro and Zepbound sales surged while Novo's Ozempic and Wegovy stalled, and Lilly's oral pill Foundayo is just starting. Viking's oral VK2735 phase 3 is planned for late 2026. A fast-growing market with an unsettled oral segment keeps Viking's pipeline valuable, supporting the stock.

    It shows the competitive landscape that makes Viking's oral and injectable programs strategically valuable.

  • Cash burn and capital needs remain the overhang Viking used about $96 million last quarter and cash fell to $502 million from $706 million. Management says cash lasts into 2028, but the new raise confirms trials are expensive. Until VK2735 reaches market, funding needs and dilution risk will keep weighing on the stock even as data improves.

    It explains the persistent financial pressure that offsets clinical optimism for VKTX.

July 2026
▲2▼1

Viking's Obesity Pipeline Advances, But Cash Burn and Valuation Risks Loom

  • VK2735 Phase 2 Shows Rapid Weight Loss, Phase 3 Data Years Away VK2735 delivered mid-teens percentage weight loss in 13 weeks, faster than oral rivals. Phase 3 results are due mid-to-late 2027, with oral data in 2028-2029. This keeps the potential $100 billion market in play, supporting Viking's valuation, but the long timeline means no near-term revenue.

    This is the core clinical update that drives Viking's long-term value and investor optimism.

  • Vertex's $10B Crinetics Deal Fuels Takeover Speculation for Viking Vertex's acquisition of Crinetics for $10 billion has reignited M&A interest in obesity drugmakers. Viking, with its late-stage VK2735 and early VK3019, is seen as a prime target. A buyout could offer a premium, but any deal depends on upcoming data and remains speculative.

    M&A speculation can significantly boost Viking's stock price by implying a potential buyout premium.

  • Q2 2026 Net Loss Widens to $128.1 Million as R&D Spending Surges Viking reported a $128.1 million net loss, more than double last year's, with R&D expenses up to $115.8 million. Cash fell to $502 million from $706 million. This rising cash burn increases the risk of future dilution or financing, pressuring the stock.

    The widening loss and shrinking cash highlight the financial strain of funding late-stage trials, a key risk for a pre-revenue company.

  • Analyst Valuation Gap: 120% Undervalued vs. DCF Overvalued One analyst narrative sees Viking 120% undervalued at $92.72 per share, while a DCF model suggests it's overvalued at $14.02. This huge discrepancy reflects uncertainty over pipeline success and funding needs, making the stock volatile and hard to value.

    The stark valuation divide shows the market's uncertainty about Viking's prospects, which can cause sharp price swings.

▲2▼1

Viking's Obesity Pipeline Advances, But Cash Burn and Valuation Risks Loom

  • VK2735 Phase 2 Shows Rapid Weight Loss, Phase 3 Data Years Away VK2735 delivered mid-teens percentage weight loss in 13 weeks, faster than oral rivals. Phase 3 results are due mid-to-late 2027, with oral data in 2028-2029. This keeps the potential $100 billion market in play, supporting Viking's valuation, but the long timeline means no near-term revenue.

    This is the core clinical update that drives Viking's long-term value and investor optimism.

  • Vertex's $10B Crinetics Deal Fuels Takeover Speculation for Viking Vertex's acquisition of Crinetics for $10 billion has reignited M&A interest in obesity drugmakers. Viking, with its late-stage VK2735 and early VK3019, is seen as a prime target. A buyout could offer a premium, but any deal depends on upcoming data and remains speculative.

    M&A speculation can significantly boost Viking's stock price by implying a potential buyout premium.

  • Q2 2026 Net Loss Widens to $128.1 Million as R&D Spending Surges Viking reported a $128.1 million net loss, more than double last year's, with R&D expenses up to $115.8 million. Cash fell to $502 million from $706 million. This rising cash burn increases the risk of future dilution or financing, pressuring the stock.

    The widening loss and shrinking cash highlight the financial strain of funding late-stage trials, a key risk for a pre-revenue company.

  • Analyst Valuation Gap: 120% Undervalued vs. DCF Overvalued One analyst narrative sees Viking 120% undervalued at $92.72 per share, while a DCF model suggests it's overvalued at $14.02. This huge discrepancy reflects uncertainty over pipeline success and funding needs, making the stock volatile and hard to value.

    The stark valuation divide shows the market's uncertainty about Viking's prospects, which can cause sharp price swings.

Q2 2026
▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

  • Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.

    New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.

  • VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.

    New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.

  • VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.

    The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.

  • Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.

    Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

June 2026
▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

  • Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.

    New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.

  • VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.

    New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.

  • VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.

    The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.

  • Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.

    Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

  • Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.

    New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.

  • VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.

    New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.

  • VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.

    The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.

  • Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.

    Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

AbbVie Inc (ABBV)

Q3 2026
▲2▼2

AbbVie Q3: Earnings Beat, Pipeline Wins, But Pricing and Trial Setbacks

  • Strong Q2 Earnings and Raised Guidance AbbVie's Q2 EPS and revenue beat estimates, and the company raised full-year revenue guidance. Skyrizi and Rinvoq now make up over 47% of revenue, offsetting Humira's decline. Neuroscience guidance also increased to about $12.7 billion.

    This shows the core business outperformed and management is optimistic about future growth.

  • Pipeline Progress and New Approvals AbbVie reported Phase 3 successes, received EU approvals, and gained FDA approval for JUVMO. These advances strengthen the company's drug portfolio and future revenue potential.

    New drug approvals and trial wins are key drivers of long-term growth and investor confidence.

  • EPCORE DLBCL-1 Trial Miss and Guidance Cut The EPCORE DLBCL-1 trial missed its endpoint, leading AbbVie to cut profit guidance. The stock dropped 4% on the news, highlighting pipeline risks.

    This was a major setback that directly hurt earnings expectations and investor sentiment.

  • Pricing Pressures and Competitive Threats Trump demanded U.S. price cuts, and J&J's oral psoriasis pill won Chinese approval. Apogee's $10.9 billion acquisition will dilute earnings until 2032, and oncology sales fell 2.8% as Imbruvica dropped 27.1%.

    These factors create headwinds for revenue and profitability, weighing on the stock.

September 2026
▲2▼2

AbbVie's Pipeline Wins Offset Apogee Dilution and Oncology Decline

  • Pipeline Momentum AbbVie reported multiple Phase 3 wins: etentamig for myeloma, Qulipta for menstrual migraine, and RINVOQ for vitiligo. EU approved Rinvoq for juvenile arthritis, and the FDA approved JUVMO for Parkinson's. Early-stage data for zumilokibart and ABBV-295 also showed promise.

    These pipeline successes signal future growth and strengthen AbbVie's competitive position.

  • Neuroscience Guidance Raised AbbVie raised its neuroscience revenue guidance to about $12.7 billion, with total revenue near $67.6 billion. This reflects confidence in its neuroscience portfolio and overall business strength.

    Higher guidance indicates management's optimism and potential for earnings growth.

  • Apogee Acquisition Dilutes Earnings The $10.9 billion Apogee acquisition will reduce earnings by $0.14 per share in 2026 and $0.46 in 2027, with profits not expected until 2032. This near-term dilution pressures the stock.

    The acquisition's dilution is a significant near-term headwind for earnings per share.

  • Oncology Sales Decline Oncology sales fell 2.8% as Imbruvica dropped 27.1% due to competition and IRA pricing. Newer drugs did not fully offset the decline, highlighting challenges in this segment.

    The decline in oncology revenue weighs on overall growth and profitability.

Latest
▲4

AbbVie's pipeline wins and new drug approvals drive growth outlook

  • FDA approves JUVMO for Parkinson's disease The FDA approved JUVMO (tavapadon), the first selective D1/D5 agonist for Parkinson's, with U.S. launch set for October 2026. This adds a differentiated neuroscience drug to AbbVie's portfolio, supporting future revenue growth and lifting investor confidence.

    A major new drug approval directly expands AbbVie's revenue base and pipeline strength.

  • Zumilokibart succeeds in Phase 2 atopic dermatitis trial AbbVie's zumilokibart met the main goal in a Phase 2 study for atopic dermatitis, and the mid-dose will move into final-stage testing. This strengthens the immunology pipeline and offers a potential new treatment for a common skin condition, supporting long-term growth.

    Positive mid-stage trial results advance a key pipeline candidate, signaling future revenue potential.

  • ABBV-295 shows promising weight loss and long half-life Phase 1 data for ABBV-295 showed up to 9.8% weight loss and an 11-12 day half-life, supporting less frequent dosing. This opens a new market for AbbVie in obesity care, a high-growth area, and could become a significant future sales driver.

    Early data support a potential best-in-class obesity drug, a major new growth opportunity.

  • RINVOQ shows sustained vitiligo repigmentation in Phase 3 Phase 3 data show RINVOQ produced continued skin repigmentation in vitiligo through 76 weeks with no new safety issues. This supports a potential new use for a key drug, expanding its label and adding a new revenue stream if approved.

    Late-stage data support a new indication for a major drug, enhancing its growth prospects.

▲3▼1

AbbVie's pipeline and label wins offset oncology and pricing headwinds

  • Qulipta hits Phase 3 goal in menstrual migraine Qulipta met the main goal and all secondary goals in a late-stage trial for menstrual migraine, a condition with no approved treatment. If approved, it opens a new market of over nine million U.S. patients, adding a fresh sales driver and supporting the stock.

    New clinical win expands a fast-growing drug into an untapped market, a clear positive for future revenue.

  • Rinvoq wins EU approval for juvenile arthritis European regulators approved Rinvoq for polyarticular juvenile idiopathic arthritis, its 11th EU use. This widens the label of a key growth drug already on track for about $10.2 billion in 2026 sales, reinforcing confidence in AbbVie's immunology growth.

    New regulatory approval directly expands a major growth drug's market and supports the bull case.

  • AI drug-discovery deals and EPKINLY approval AbbVie signed multi-year AI collaborations with Iambic and joined the AISB Bind network to speed up drug discovery, and Health Canada approved EPKINLY for relapsed follicular lymphoma. These broaden the pipeline and add a new approved use, supporting long-term growth.

    New partnerships and a new approval show pipeline expansion and fresh revenue potential.

  • Oncology sales fall on Imbruvica and IRA pricing First-half oncology sales dropped 2.8% to $3.28 billion as Imbruvica fell 27.1% on competition and Medicare drug-price changes. Newer drugs like Venclexta and Elahere grew but did not fully offset the decline, weighing on overall growth.

    A real counterweight: a key segment is shrinking due to competition and pricing pressure.

▲3▼1

AbbVie's pipeline and guidance wins offset Apogee dilution

  • Apogee acquisition dilutes near-term earnings AbbVie closed its $10.9 billion purchase of Apogee Therapeutics, adding an experimental immunology drug but cutting adjusted earnings by $0.14 per share in 2026 and $0.46 in 2027. Profit won't get a boost until 2032, so near-term investors see lower earnings and the stock faces pressure.

    This is the main new negative event this period and directly lowers reported earnings, a key driver of the stock price.

  • Etentamig succeeds in Phase 3 myeloma trial AbbVie's experimental blood-cancer drug etentamig met both main goals in a late-stage trial, with a 74% response rate versus 46% for standard care and a 60% lower risk of disease worsening. This strengthens the oncology pipeline and raises hopes for a new growth driver, supporting the stock.

    This is a major new clinical win that expands AbbVie's cancer franchise and improves long-term growth prospects.

  • Qulipta succeeds in menstrual migraine trial AbbVie's migraine drug Qulipta hit the main goal in a Phase 3 trial for menstrual migraine, reducing migraine days with a convenient dosing schedule. Qulipta sales already grew 31% to $350 million last quarter, so a new use could add revenue and lift the stock.

    This is a new positive trial result that could expand the label and sales of an already fast-growing drug.

  • Neuroscience outlook raised on broad growth AbbVie lifted its 2026 neuroscience revenue forecast to about $12.7 billion and total revenue to roughly $67.6 billion, after first-half neuroscience sales jumped 21.8%. Strong demand across Vraylar, Botox, Qulipta, Ubrelvy and Vyalev gives investors more confidence in future profits, pushing the stock up.

    This is a new guidance raise that directly improves revenue expectations and signals broad-based demand strength.

August 2026
▲3▼2

AbbVie's Skyrizi-Rinvoq Momentum Outweighs Pricing and Competition Risks

  • Skyrizi and Rinvoq Now Over 47% of Revenue AbbVie's two newer drugs, Skyrizi and Rinvoq, now make up more than 47% of total revenue and are expected to top $31 billion this year, more than offsetting declining sales of older Humira.

    This shows the core growth engine replacing Humira, a key positive force for the stock.

  • Neuroscience Guidance Raised and Pipeline Advances AbbVie raised its neuroscience revenue guidance to about $12.7 billion, and reported promising lung cancer data plus a European filing for a subcutaneous version of Skyrizi for Crohn's disease, strengthening future growth prospects.

    These pipeline and guidance updates point to new sources of revenue and expanded use of existing drugs.

  • Citadel Hedge Fund Boosts Stake 547% Citadel, a major hedge fund, increased its ownership stake in AbbVie by 547%, a sign that some large investors see strong value in the company despite recent concerns.

    A big institutional buyer can lift sentiment and signal confidence in the stock.

  • Trump Demands U.S. Price Cuts Within 60 Days President Trump demanded that AbbVie cut U.S. drug prices within 60 days, threatening its pricing power and adding regulatory uncertainty that could pressure revenue and profit margins.

    This is a new political risk that directly challenges AbbVie's ability to set prices in its largest market.

  • J&J's Oral Psoriasis Pill Wins Chinese Approval Johnson & Johnson's oral psoriasis pill Icotyde received approval in China, where 8.4 million patients could switch from injectable treatments like AbbVie's Skyrizi, posing a competitive threat in a key growth market.

    This new competition could slow Skyrizi's expansion and take market share.

▲3▼1

AbbVie's pipeline and franchise expansion offset profit-guidance cut

  • Citadel boosts AbbVie stake by 547% Ken Griffin's Citadel bought 2.68 million more ABBV shares, a 547% increase, at an average of $214.90. A major fund raising its bet signals confidence in AbbVie's long-term value and can draw other investors in, supporting the stock price.

    Large institutional buying is a fresh, concrete signal of confidence that can lift investor sentiment and demand for the shares.

  • New lung cancer data strengthens oncology pipeline AbbVie presented promising early data for several experimental lung cancer drugs at a major conference, with high response rates and manageable side effects. This broadens its pipeline beyond immunology and neuroscience, giving investors another potential growth engine and supporting the stock.

    Fresh clinical progress on multiple oncology programs adds a new growth pillar, which can improve the long-term earnings outlook.

  • Skyrizi submitted for easier Crohn's dosing in Europe AbbVie asked European regulators to approve Skyrizi as a subcutaneous (under-the-skin) induction treatment for Crohn's disease, based on positive trial data. If approved, it offers patients a more convenient option and extends Skyrizi's reach, supporting future sales and the stock.

    A regulatory filing that could widen a key drug's use is a concrete pipeline expansion, not just a repeat of past results.

  • J&J's oral psoriasis pill approved in China Johnson & Johnson won Chinese approval for Icotyde, a once-daily pill for plaque psoriasis, a market with over 8.4 million patients where AbbVie's Skyrizi competes. A convenient oral option could take share from injectables like Skyrizi, weighing on AbbVie's growth prospects in China.

    This is a new competitive threat in a large market that could pressure sales of a key AbbVie drug.

▲2▼2

AbbVie's core drugs stay strong, but pricing pressure and pipeline setback weigh

  • Trump demands drug price cuts President Trump sent letters to major drugmakers, including AbbVie, demanding U.S. prescription price cuts within 60 days. This threatens future pricing power and revenue, pushing the stock down as investors worry about lower profits.

    This is a new regulatory threat that directly pressures AbbVie's pricing and future earnings.

  • Skyrizi and Rinvoq fuel growth AbbVie's newer immunology drugs Skyrizi and Rinvoq now make up over 47% of total revenue, with combined sales expected to exceed $31 billion this year. Their rapid growth is replacing declining Humira sales and supports the stock's long-term value.

    This shows the core business is successfully transitioning beyond Humira, a key driver of future revenue.

  • Neuroscience outlook raised AbbVie raised its 2026 neuroscience revenue forecast to about $12.7 billion, driven by strong sales of Vraylar, migraine drugs Ubrelvy and Qulipta, and Botox Therapeutic. This diversification adds a growing revenue stream and boosts investor confidence.

    This is a new positive update showing another part of AbbVie's business is performing well and raising guidance.

  • Epcoritamab trial fails survival goal Genmab and AbbVie confirmed that the Phase 3 trial of epcoritamab for a type of lymphoma did not meet its main overall survival goal. This pipeline setback could delay or reduce the drug's potential, weighing on sentiment.

    This is a new negative pipeline event that could hurt future oncology revenue prospects.

July 2026
▲3▼1

AbbVie's Q2 Beat and EU Approvals Offset by Trial Miss and Profit Guidance Cut

  • EU Approvals Expand Drug Labels AbbVie won European approvals for TEPKINLY in follicular lymphoma, Boey for frown lines, and RINVOQ for alopecia areata, broadening its oncology, aesthetics, and immunology offerings. These label expansions can drive future revenue growth.

    New approvals are a key positive development that can boost investor confidence and future sales.

  • Q2 Earnings Beat and Guidance Raise AbbVie reported Q2 EPS of $3.65 and revenue of $16.99 billion, beating estimates. Management raised full-year revenue guidance by $300 million, citing strong growth in Skyrizi, Rinvoq, and neuroscience.

    The earnings beat and guidance raise show operational strength and support the bull case.

  • Voluntary Pricing Deals Reduce Uncertainty AbbVie entered voluntary most-favored-nation pricing agreements, which lessen regulatory uncertainty around drug pricing. This proactive step may stabilize the pricing environment and reduce political risk.

    Reduced regulatory uncertainty is a positive for the stock as it removes a potential overhang.

  • Trial Miss and Profit Guidance Cut The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint, hurting oncology sentiment. Additionally, a $291 million acquired IPR&D charge led AbbVie to cut full-year adjusted earnings guidance, sending shares down 4%.

    The trial failure and earnings guidance cut are significant negatives that pressured the stock.

▲2▼2

AbbVie beats Q2, raises revenue outlook, but full-year profit guidance cut

  • Q2 beat and raised revenue guidance AbbVie beat Q2 estimates with $3.65 EPS and $16.99B revenue, and raised full-year revenue guidance by $300M on strong Skyrizi, Rinvoq and neuroscience growth. This shows the core business is performing well, supporting the stock's long-term value.

    This is the main new positive event this period, directly driving the stock's fundamental outlook.

  • Full-year profit guidance lowered Despite the revenue beat, AbbVie cut its full-year adjusted earnings outlook, partly due to a $291M charge for acquired IPR&D and milestone expenses. This disappointed investors and caused shares to fall 4%, as it signals near-term profit pressure.

    This is the key negative event this period, explaining the immediate stock drop and investor concern.

  • EU approval of RINVOQ for alopecia areata AbbVie won European approval for RINVOQ in severe alopecia areata, expanding its immunology franchise. This adds a new revenue stream and reinforces RINVOQ's growth potential, which is positive for the stock.

    This is a new regulatory win that expands the market for a key drug, supporting future sales.

  • Epcoritamab trial setback The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint in the U.S., a setback for AbbVie's oncology pipeline. This could delay or reduce the drug's potential, weighing on sentiment.

    This is a new negative pipeline event that affects future growth prospects.

▲3▼1

AbbVie's pipeline wins approvals but faces trial setback and new competition

  • EU approval of TEPKINLY for follicular lymphoma The European Commission approved AbbVie's TEPKINLY combination for relapsed follicular lymphoma, a chemotherapy-free option that cut progression risk by 79%. This expands AbbVie's oncology portfolio and adds a new revenue stream, supporting long-term growth.

    New approval directly boosts AbbVie's oncology franchise and future sales.

  • EU approval of Boey for frown lines Allergan Aesthetics, part of AbbVie, won EU approval for Boey, a fast-acting botulinum toxin for frown lines. This strengthens AbbVie's aesthetics business and offers a new treatment option, potentially driving revenue growth.

    New product approval expands AbbVie's aesthetics portfolio and revenue potential.

  • Voluntary drug-pricing deals with Trump administration AbbVie agreed to voluntary most-favored-nation pricing with the Trump administration. While this may lower prices for some drugs, AbbVie's newer immunology drugs Skyrizi and Rinvoq are expected to offset Humira's decline, and the deal reduces regulatory uncertainty.

    New pricing agreement affects AbbVie's revenue but is manageable given strong new drugs.

  • Epcoritamab trial misses overall survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial did not meet its primary overall survival endpoint in the U.S. This setback could delay or reduce the drug's potential in this indication, weighing on sentiment.

    New negative trial result directly impacts AbbVie's oncology pipeline and investor confidence.

Q2 2026
▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

  • Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.

    This major acquisition is a key new event that could drive future growth and investor sentiment.

  • Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.

    These clinical and regulatory successes directly boosted the stock price and market value.

  • Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.

    This regulatory risk is a new negative factor that could weigh on the stock.

  • Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.

    Slowing growth is a fundamental concern that could limit upside for the stock.

June 2026
▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

  • Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.

    This major acquisition is a key new event that could drive future growth and investor sentiment.

  • Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.

    These clinical and regulatory successes directly boosted the stock price and market value.

  • Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.

    This regulatory risk is a new negative factor that could weigh on the stock.

  • Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.

    Slowing growth is a fundamental concern that could limit upside for the stock.

▲2▼2

AbbVie hits 52-week high on Apogee deal and drug approvals, but China probe and slowing drug growth weigh

  • Apogee acquisition and expanded drug labels drive record high AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, adding a promising immunology drug. It also won approvals to expand Skyrizi and Rinvoq to new patient groups. These moves strengthen future growth and pushed the stock to a 52-week high, adding $43 billion in market value in a week.

    This is the main reason the stock hit a new high and reflects the biggest new development this period.

  • US Congress opens bipartisan probe into AbbVie's China clinical trials A House committee is investigating AbbVie's clinical trials in China, including sites linked to the Chinese military and in Xinjiang. While no illegal conduct is alleged, the probe could lead to tighter oversight, higher compliance costs, and restrictions on trial locations, potentially delaying drug pipelines and hurting the stock.

    This is a new risk that could negatively affect the stock and was not in earlier reports.

  • Growth of key drugs Skyrizi and Rinvoq shows signs of slowing Skyrizi's growth decelerated to 29.2% from 31.9%, and Rinvoq's growth slowed to 20.2% from 28.6%. These drugs are critical to AbbVie's post-Humira strategy, and any sustained slowdown could pressure the stock's valuation, which already prices in high growth.

    This is a new concern about the company's growth engine that could weigh on the stock.

  • Positive late-stage trial results and new drug approvals bolster pipeline AbbVie reported positive Phase 3 data for venetoclax in leukemia and epcoritamab in lymphoma, and won approvals for MAVIRET in hepatitis C, SKYRIZI in pediatric psoriasis, and a new neurotoxin Boey. These advances strengthen the company's oncology and aesthetics portfolios, supporting long-term revenue growth.

    These are new clinical and regulatory wins that reinforce AbbVie's pipeline and future sales potential.

▲3

AbbVie's $10.9B Apogee buy expands immunology pipeline

  • Apogee acquisition adds promising immunology drug AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining zumilokibart, a potential rival to Dupixent for eczema and asthma. The deal strengthens AbbVie's immunology franchise and pipeline, which investors view as a positive for long-term growth.

    This is the main new event driving ABBV's stock and future prospects.

  • Deal funded without debt, preserving financial flexibility AbbVie will pay for Apogee entirely from operating cash flow, avoiding new debt. This keeps its balance sheet strong and reduces financial risk, which supports the stock price.

    Shows the acquisition is financially manageable and not a strain.

  • Near-term earnings dilution, but long-term growth The deal won't add to adjusted earnings per share until 2032, so it may slightly weigh on near-term profits. However, it positions AbbVie for future growth in immunology, balancing the short-term cost with long-term benefit.

    Highlights the trade-off investors are weighing.

  • Analysts see reasonable premium and strategic fit Citi and other analysts said the 49% premium is not excessive given Apogee's strong data and scarce immunology assets. The deal also fits with AbbVie's existing commercial infrastructure, supporting a positive view.

    Analyst validation reinforces the market's positive reaction.

© 2026 MarketIVWhy